debrisoquin has been researched along with Metabolic Diseases in 3 studies
Debrisoquin: An adrenergic neuron-blocking drug similar in effects to GUANETHIDINE. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
Metabolic Diseases: Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bertilsson, L | 1 |
| Dahl, ML | 1 |
| Sjöqvist, F | 1 |
| Aberg-Wistedt, A | 1 |
| Humble, M | 1 |
| Johansson, I | 1 |
| Lundqvist, E | 1 |
| Ingelman-Sundberg, M | 1 |
| Agúndez, JA | 1 |
| Benítez, J | 1 |
| Garrick, R | 1 |
| Ewan, CE | 1 |
| Bauer, GE | 1 |
| Neale, FC | 1 |
3 other studies available for debrisoquin and Metabolic Diseases
| Article | Year |
|---|---|
Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine.
Topics: Debrisoquin; Female; Humans; Hydroxylation; Metabolic Diseases; Neurotic Disorders; Polymorphism, Re | 1993 |
Debrisoquine polymorphism: mechanism for very rapid oxidative phenotype.
Topics: Debrisoquin; Europe; Humans; Hydroxylation; Metabolic Diseases; Mixed Function Oxygenases; Phenotype | 1993 |
Serum uric acid in normal and hypertensive Australian subjects.
Topics: Adolescent; Adult; Age Factors; Australia; Child; Colorimetry; Debrisoquin; Female; Guanethidine; Hu | 1972 |